MRSA Infections in HIV-Infected People Are Associated with Decreased MRSA-Specific Th1 Immunity

Netanya S Utay, Annelys Roque, J Katherina Timmer, David R Morcock, Claire DeLeage, Anoma Somasunderam, Amy C Weintrob, Brian K Agan, Jacob D Estes, Nancy F Crum-Cianflone, Daniel C Douek, Netanya S Utay, Annelys Roque, J Katherina Timmer, David R Morcock, Claire DeLeage, Anoma Somasunderam, Amy C Weintrob, Brian K Agan, Jacob D Estes, Nancy F Crum-Cianflone, Daniel C Douek

Abstract

People with HIV infection are at increased risk for community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) skin and soft tissue infections (SSTIs). Lower CD4 T-cell counts, higher peak HIV RNA levels and epidemiological factors may be associated with increased risk but no specific immune defect has been identified. We aimed to determine the immunologic perturbations that predispose HIV-infected people to MRSA SSTIs. Participants with or without HIV infection and with MRSA SSTI, MRSA colonization or negative for MRSA were enrolled. Peripheral blood and skin biopsies from study participants were collected. Flow cytometry, flow cytometry with microscopy, multiplex assays of cell culture supernatants and immunohistochemistry were used to evaluate the nature of the immune defect predisposing HIV-infected people to MRSA infections. We found deficient MRSA-specific IFNγ+ CD4 T-cell responses in HIV-infected people with MRSA SSTIs compared to MRSA-colonized participants and HIV-uninfected participants with MRSA SSTIs. These IFNγ+ CD4 T cells were less polyfunctional in HIV-infected participants with SSTIs compared to those without SSTIs. However, IFNγ responses to cytomegalovirus and Mycobacterium avium antigens and MRSA-specific IL-17 responses by CD4 T cells were intact. Upon stimulation with MRSA, peripheral blood mononuclear cells from HIV-infected participants produced less IL-12 and IL-15, key drivers of IFNγ production. There were no defects in CD8 T-cell responses, monocyte responses, opsonization, or phagocytosis of Staphylococcus aureus. Accumulation of CD3 T cells, CD4 T cells, IL-17+ cells, myeloperoxidase+ neutrophils and macrophage/myeloid cells to the skin lesions were similar between HIV-infected and HIV-uninfected participants based on immunohistochemistry. Together, these results indicate that MRSA-specific IFNγ+ CD4 T-cell responses are essential for the control of initial and recurrent MRSA infections in HIV-infected people.

Conflict of interest statement

I have read the journal's policy and the authors of this manuscript have the following competing interests: DRM: Leidos Biomedical Research, Inc (employment); JDE: Leidos Biomedical Research, Inc (employment); NSU: Tobira Therapeutics, Inc (scientific advisory board, research funds, travel); EnteraHealth, Inc (research funds); Gilead Sciences, Inc (travel funds).

Figures

Fig 1. MRSA-specific memory CD4 T cells.
Fig 1. MRSA-specific memory CD4 T cells.
Flow cytometry analysis of MRSA-specific memory (CD27+CD45RO+ or CD27-) CD4 T-cell responses in HIV-infected or HIV-uninfected participants with MRSA SSTI, colonization or neither. Frequency of memory CD4 T cells producing (A) IFNγ, (B) IL-17, (C) TNF and (D) CD40L. For all figures, horizontal lines indicate medians. P-values were calculated using the Mann-Whitney U test.
Fig 2. Cytokine concentrations released into supernatant.
Fig 2. Cytokine concentrations released into supernatant.
Supernatant concentrations of IFNγ (A) and drivers of IFNγ production, IL-12 (B) and IL-15 (C), after MRSA stimulation of PBMCs were assayed using the Luminex platform. P-values were calculated using the Mann-Whitney U test.
Fig 3. Histological evaluation of skin biopsies.
Fig 3. Histological evaluation of skin biopsies.
Skin biopsies were obtained from MRSA SSTI participants at the infection site (SSTI lesion) or a distant site (SSTI Not Lesion), or MRSA-negative participants (-). (A) Abundance of CD3. (B) Abundance of CD4. (C) Abundance of IL-17. (D) Abundance of neutrophils (myeloperoxidase+ [MPO]). (E) Abundance of macrophage/myeloid cells (CD68+ and/or CD163+). P-values were calculated using the Mann-Whitney U test.

References

    1. Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis. 2007;44(6):777–84.
    1. Zervou FN, Zacharioudakis IM, Ziakas PD, Rich JD, Mylonakis E. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus colonization in HIV infection: a meta-analysis. Clin Infect Dis. 2014;59(9):1302–11. 10.1093/cid/ciu559
    1. Crum-Cianflone NF, Burgi AA, Hale BR. Increasing rates of community-acquired methicillin-resistant Staphylococcus aureus infections among HIV-infected persons. Int J STD AIDS. 2007;18(8):521–6.
    1. Shadyab AH, Crum-Cianflone NF. Methicillin-resistant Staphylococcus aureus (MRSA) infections among HIV-infected persons in the era of highly active antiretroviral therapy: a review of the literature. HIV Med. 2012;13(6):319–32. 10.1111/j.1468-1293.2011.00978.x
    1. Beekhuizen H, van de Gevel JS. Gamma interferon confers resistance to infection with Staphylococcus aureus in human vascular endothelial cells by cooperative proinflammatory and enhanced intrinsic antibacterial activities. Infect Immun. 2007;75(12):5615–26.
    1. Sasaki S, Tagawa Y, Iwakura Y, Nakane A. The role of gamma interferon in acquired host resistance against Staphylococcus aureus infection in mice. FEMS Immunol Med Microbiol. 2006;46(3):367–74.
    1. Conte D, Fraquelli M, Capsoni F, Giacca M, Zentilin L, Bardella MT. Effectiveness of IFN-gamma for liver abscesses in chronic granulomatous disease. J Interferon Cytokine Res. 1999;19(7):705–10.
    1. Proctor RA. Challenges for a universal Staphylococcus aureus vaccine. Clin Infect Dis. 2012;54(8):1179–86. 10.1093/cid/cis033
    1. Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 2008;452(7188):773–6. 10.1038/nature06764
    1. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol. 2012;10(9):655–66. 10.1038/nrmicro2848
    1. Miller CH, Maher SG, Young HA. Clinical Use of Interferon-gamma. Ann N Y Acad Sci. 2009;1182:69–79. 10.1111/j.1749-6632.2009.05069.x
    1. Vafai A, Berger M. Zoster in patients infected with HIV: a review. The American journal of the medical sciences. 2001;321(6):372–80.
    1. Van de Perre P, Segondy M, Foulongne V, Ouedraogo A, Konate I, Huraux JM, et al. Herpes simplex virus and HIV-1: deciphering viral synergy. The Lancet Infectious diseases. 2008;8(8):490–7. 10.1016/S1473-3099(08)70181-6
    1. Vukmanovic-Stejic M, Sandhu D, Seidel JA, Patel N, Sobande TO, Agius E, et al. The Characterization of Varicella Zoster Virus-Specific T Cells in Skin and Blood during Aging. The Journal of investigative dermatology. 2015;135(7):1752–62. 10.1038/jid.2015.63
    1. Watanabe D, Otani N, Suzuki S, Dohi H, Hirota K, Yonemoto H, et al. Evaluation of VZV-specific cell-mediated immunity in adults infected with HIV-1 by using a simple IFN-gamma release assay. Journal of medical virology. 2013;85(8):1313–20. 10.1002/jmv.23611
    1. Iijima N, Linehan MM, Zamora M, Butkus D, Dunn R, Kehry MR, et al. Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus. The Journal of experimental medicine. 2008;205(13):3041–52. 10.1084/jem.20082039
    1. Palmer BE, Blyveis N, Fontenot AP, Wilson CC. Functional and phenotypic characterization of CD57+CD4+ T cells and their association with HIV-1-induced T cell dysfunction. Journal of immunology (Baltimore, Md: 1950). 2005;175(12):8415–23.
    1. Tanaskovic S, Fernandez S, Price P, French MA. Interleukin-7 signalling defects in naive CD4+ T cells of HIV patients with CD4+ T-cell deficiency on antiretroviral therapy are associated with T-cell activation and senescence. AIDS (London, England). 2014;28(6):821–30.
    1. Unemori P, Leslie KS, Hunt PW, Sinclair E, Epling L, Mitsuyasu R, et al. Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection. AIDS (London, England). 2013;27(11):1735–42.
    1. Stuyt RJ, Netea MG, Kim SH, Novick D, Rubinstein M, Kullberg BJ, et al. Differential roles of interleukin-18 (IL-18) and IL12 for induction of gamma interferon by staphylococcal cell wall components and superantigens. Infect Immun. 2001;69(8):5025–30.
    1. Marshall JD, Chehimi J, Gri G, Kostman JR, Montaner LJ, Trinchieri G. The interleukin-12-mediated pathway of immune events is dysfunctional in human immunodeficiency virus-infected individuals. Blood. 1999;94(3):1003–11.
    1. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3(2):133–46.
    1. Prando C, Samarina A, Bustamante J, Boisson-Dupuis S, Cobat A, Picard C, et al. Inherited IL-12p40 deficiency: genetic, immunologic, and clinical features of 49 patients from 30 kindreds. Medicine (Baltimore). 2013;92(2):109–22.
    1. de Beaucoudrey L, Samarina A, Bustamante J, Cobat A, Boisson-Dupuis S, Feinberg J, et al. Revisiting human IL-12Rbeta1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore). 2010;89(6):381–402.
    1. Netea MG, Kullberg BJ, van der Meer JW. Severely impaired IL-12/IL-18/IFNgamma axis in patients with hyper IgE syndrome. Eur J Clin Invest. 2005;35(11):718–21.
    1. Musso T, Calosso L, Zucca M, Millesimo M, Ravarino D, Giovarelli M, et al. Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood. 1999;93(10):3531–9.
    1. Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother. 2007;51(2):423–8.
    1. Bassetti M, Trecarichi EM, Mesini A, Spanu T, Giacobbe DR, Rossi M, et al. Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2012;18(9):862–9.
    1. Murphy PM, Lane HC, Gallin JI, Fauci AS. Marked disparity in incidence of bacterial infections in patients with the acquired immunodeficiency syndrome receiving interleukin-2 or interferon-gamma. Ann Intern Med. 1988;108(1):36–41.
    1. Abrams D, Levy Y, Losso MH, Babiker A, Collins G, Cooper DA, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009;361(16):1548–59. 10.1056/NEJMoa0903175
    1. Hao XP, Lucero CM, Turkbey B, Bernardo ML, Morcock DR, Deleage C, et al. Experimental colitis in SIV-uninfected rhesus macaques recapitulates important features of pathogenic SIV infection. Nature communications. 2015;6:8020 10.1038/ncomms9020

Source: PubMed

3
Iratkozz fel